Lumier Pharma LLC is a domestic manufacturer of pharmaceuticals. The company was established in 2009 in Kyiv, Ukraine. The scope of the company’s main activities encompasses the production of vital prescription medicines for the treatment of oncological diseases, tuberculosis, blood diseases, and varieties of chronic viral hepatitis. At present, the company’s product portfolio features 14 medication items.

The company’s top-priority efforts are directed at the establishment and development of long-term partner relations with the world’s leading pharmaceutical companies within the framework of the import substitution policy in Ukraine aimed at the improvement of accessibility of high quality medicines for all patients.

In 2011, the world’s leading manufacturer of pharmaceuticals, the F.Hoffmann-La Roche Ltd Company, and the domestic company Lumier Pharma implemented a mutual social project aimed at improving the accessibility of medications and the quality of medicines, as well as optimizing treatment results in patients with viral hepatitis diseases and HIV/AIDS with co-infection.

Lumier Pharma LLC provides medication and medical-purpose goods packing and repacking services in conformity with all Ukrainian legislation and EU GMP requirements. 

At the beginning of 2012, Lumier Pharma registered two medications developed by the F.Hoffmann-La Roche Ltd Company that will be produced in Ukraine in the framework of a mutual project with Lumier Pharma

  • RITUXIM (rituximab), a concentrate for the preparation of infusion solution in vials of 100mg/10 ml and 500mg/50 ml – for the treatment of hematological illnesses.
  • TRASTUMAB (trastuzumab), powder for the preparation of concentrate for infusion, in vials of 150 mg each – for the treatment of mammary gland cancer.